CEMI Chembio Diagnostics Inc.

Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System

Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System
EN
02/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Chembio Diagnostics Inc.

 PRESS RELEASE

Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

Biosynex Completes Acquisition of Chembio Diagnostics, Inc. Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. (“Chembio”), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The complementary nature of the technologi...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: April 25, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: April 20, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York...

Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023 Failure to tender shares could result in the termination of the proposed merger between Chembio and Biosynex MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 Fellow Chembio Stockholders, We strongly urge you to tender your shares of common stock ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch